🔴 CMPS is trading 6.5% down today after Phase 3 COMP360 durability data update

CMPS is trading 6.5% down at $12.00 as investors digest new Phase 3 COMP360 durability data for treatment-resistant depression.

• The company reported positive 26-week results from its second Phase 3 trial, confirming a rapid and durable response to the treatment.
• Despite the positive clinical data, the stock is pulling back following a sharp recent run-up as the market reassesses valuation and regulatory timelines.